SDGR250117P20000
- 1.15
- -0.21-15.44%
Schrodinger Newsroom
2024's 'Biggest Loses' That Could See Reversal in 2025
AI Driven Drug Discovery Patent Landscape Report 2024: 1,087 Patents Analyzed With Market Sales Data and Growth Rates - ResearchAndMarkets.com
Stocks With Improving and Deteriorating 'TechniGrade' by Piper Sandler
Schrödinger to Present at Piper Sandler 36th Annual Healthcare Conference
Express News | Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Schrodinger Inc: Received an Additional $9.5 Mln From Bill & Melinda Gates Foundation
Schrödinger Broadens and Accelerates Predictive Toxicology Initiative
Goldman Sachs Maintains Schrodinger(SDGR.US) With Hold Rating, Raises Target Price to $28
Schrodinger Is Maintained at Outperform by BMO Capital
Schrodinger Analyst Ratings
Craig-Hallum Maintains Schrodinger(SDGR.US) With Buy Rating, Announces Target Price $30
BMO Capital Maintains Schrodinger(SDGR.US) With Buy Rating, Raises Target Price to $28
A Quick Look at Today's Ratings for Schrodinger(SDGR.US), With a Forecast Between $25 to $33
Schrodinger's Promising Growth Potential Highlighted by Novartis Partnership and Strong Fundamentals
Express News | Schrodinger Inc : BMO Raises Target Price to $28 From $25
Schrodinger Announces Expanded License Agreement With Novartis
Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues Pushing Shares 26% Higher
KeyBanc Keeps Their Buy Rating on Schrodinger (SDGR)
Q3 2024 Schrodinger Inc Earnings Call